(NASDAQ: RZLT) Rezolute's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Rezolute's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast RZLT's revenue for 2027 to be $2,163,126,786, with the lowest RZLT revenue forecast at $344,175,085, and the highest RZLT revenue forecast at $3,428,129,142. On average, 3 Wall Street analysts forecast RZLT's revenue for 2028 to be $9,863,295,113, with the lowest RZLT revenue forecast at $5,009,155,059, and the highest RZLT revenue forecast at $15,018,384,040.
In 2029, RZLT is forecast to generate $20,916,854,826 in revenue, with the lowest revenue forecast at $15,167,314,683 and the highest revenue forecast at $31,349,900,461.